大小鼠压痛仪，小动物压痛仪，小动物足部压痛仪价格

库存：100

国食药监械注册号：无

保修期：12个月

现货状态：ugo大小鼠压痛仪，小动物压痛仪

供应商：上海玉研科学仪器有限公司

37215压力测试仪是经典的7200 paw压力测试仪的升级产品，自1965年首次使用以来，该测试仪在多个学术和工业实验室为镇痛药物的开发和研究做出了贡献。

压痛仪的主要特点：

· 提供三种测试量程：250g，500g，750g
· 简单可靠：无需校准！
· 标准为砝码测试型号，可根据需要选择数字显示型号；
· 提供小鼠专用型号，测量更准确；
· 1960年代以来的经典方法：发表论文数百篇！

型号：37215型

仪器的主要操作：
· 爪子放置在带有圆形尖端的锥形推动器下方的小底座上；

· 操作人员按下踏板开关，压力由小到大施加到动物的爪子上；
· 力以恒定速率增加，使得测试具备很好的可重复性；
· 动物感受到疼痛时会产生躲避反应；
· 松开踏板开关，压力立即停止；
· 在以10g为步进单位施加力；
· 采用低压同步电机，符合CE规则；
· 根据需要，可选择小鼠专用的型号；

数据采集：
· 经典的砝码款压痛仪数字模块相结合，可升级为数显型压痛仪；
· 数显型号更容易记录数据和读取数据；
· 传统款式和数显款式采用箱体的测试结构，测量数据一致；
· 数字显示器采用模块化设计，可以对传统款式进行升级；

型号：37215-BUNDLE

37215型压痛仪的主要规格

· 电源：115或230V，50/60Hz
· 功率：15W
· 操控方式：踏板开关
· 尺寸：40 x 16 x 14cm
· 重量：2.1Kg

型号和测试量程
· 37215，大鼠小鼠通用型：250g，500g，750g
· 37216，小鼠型号：125g，250g，375g

压力模块

参考文献：

1.Baloh, Robert H et al. “Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.” Nature
medicine vol. 28,9 (2022): 1813-1822. doi:10.1038/s41591-022-01956-3
2.Bosse, Gabriel D et al. “The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder.” The Journal of clinical
investigation vol. 131,10 (2021): e143990. doi:10.1172/JCI143990
3.Bang, Sangsu et al. “GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain.” The Journal of clinical investigation vol. 128,8 (2018):
3568-3582. doi:10.1172/JCI99888
4.Goebel, Andreas et al. “Passive transfer of fibromyalgia symptoms from patients to mice.” The Journal of clinical investigation vol. 131,13 (2021): e144201.
doi:10.1172/JCI144201
5.Sikandar, Shafaq et al. “Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain.” Brain : a journal of neurology vol. 141,4
(2018): 1028-1039. doi:10.1093/brain/awy009
6.Vidal-Torres, Alba et al. “Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and
safety profile compared to strong opioids.” Acta pharmaceutica Sinica. B vol. 13,1 (2023): 82-99. doi:10.1016/j.apsb.2022.09.018
7.Mousa, Shaaban A et al. “Superior control of inflammatory pain by corticotropin-releasing factor receptor 1 via opioid peptides in distinct pain-relevant brain
areas.” Journal of neuroinflammation vol. 19,1 148. 15 Jun. 2022, doi:10.1186/s12974-022-02498-8
8.Zhou, Danli et al. “Inhibition of apoptosis signal-regulating kinase by paeoniflorin attenuates neuroinflammation and ameliorates neuropathic pain.” Journal of
neuroinflammation vol. 16,1 83. 11 Apr. 2019, doi:10.1186/s12974-019-1476-6
9.Wang, Wenying et al. “Exchange factor directly activated by cAMP-PKCε signalling mediates chronic morp*hine-induced expression of purine P2X3 receptor in rat
dorsal root ganglia.” British journal of pharmacology vol. 175,10 (2018): 1760-1769. doi:10.1111/bph.14191
10.Sala, Emanuele et al. “Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morp*hine over morp*hine alone in rodent
models.” British journal of pharmacology vol. 177,14 (2020): 3291-3308. doi:10.1111/bph.15049

敬请来电咨询。

敬请关注玉研仪器微信号：yuyanbio

该产品被引用文献

1.Baloh, Robert H et al. “Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.” Nature
medicine vol. 28,9 (2022): 1813-1822. doi:10.1038/s41591-022-01956-3
2.Bosse, Gabriel D et al. “The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder.” The Journal of clinical
investigation vol. 131,10 (2021): e143990. doi:10.1172/JCI143990
3.Bang, Sangsu et al. “GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain.” The Journal of clinical investigation vol. 128,8 (2018):
3568-3582. doi:10.1172/JCI99888
4.Goebel, Andreas et al. “Passive transfer of fibromyalgia symptoms from patients to mice.” The Journal of clinical investigation vol. 131,13 (2021): e144201.
doi:10.1172/JCI144201
5.Sikandar, Shafaq et al. “Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain.” Brain : a journal of neurology vol. 141,4
(2018): 1028-1039. doi:10.1093/brain/awy009
6.Vidal-Torres, Alba et al. “Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and
safety profile compared to strong opioids.” Acta pharmaceutica Sinica. B vol. 13,1 (2023): 82-99. doi:10.1016/j.apsb.2022.09.018
7.Mousa, Shaaban A et al. “Superior control of inflammatory pain by corticotropin-releasing factor receptor 1 via opioid peptides in distinct pain-relevant brain
areas.” Journal of neuroinflammation vol. 19,1 148. 15 Jun. 2022, doi:10.1186/s12974-022-02498-8
8.Zhou, Danli et al. “Inhibition of apoptosis signal-regulating kinase by paeoniflorin attenuates neuroinflammation and ameliorates neuropathic pain.” Journal of
neuroinflammation vol. 16,1 83. 11 Apr. 2019, doi:10.1186/s12974-019-1476-6
9.Wang, Wenying et al. “Exchange factor directly activated by cAMP-PKCε signalling mediates chronic morp*hine-induced expression of purine P2X3 receptor in rat
dorsal root ganglia.” British journal of pharmacology vol. 175,10 (2018): 1760-1769. doi:10.1111/bph.14191
10.Sala, Emanuele et al. “Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morp*hine over morp*hine alone in rodent
models.” British journal of pharmacology vol. 177,14 (2020): 3291-3308. doi:10.1111/bph.15049